BPC-157 + TB-500 Stack vs LL-37
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
BPC-157 + TB-500 Stack
The most widely researched peptide stack for tissue repair, combining BPC-157 (angiogenesis and growth factor upregulation) with TB-500 (actin regulation and cell migration). The two compounds address complementary and non-overlapping stages of the healing cascade, producing synergistic effects in tendon, ligament, muscle, and gut injury research models.
Full profileLL-37
LL-37 is the only human cathelicidin — a host defense peptide produced by neutrophils, epithelial cells, and macrophages in response to infection and inflammation. It functions simultaneously as a broad-spectrum antimicrobial agent and an immune-modulatory signaling molecule. Research interest has expanded dramatically since COVID-19 studies linked low LL-37 levels to severe outcomes, and gut health research identified it as a key regulator of intestinal barrier integrity.
Full profile| BPC-157 + TB-500 Stack | LL-37 | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Wolverine Stack, BPC TB500 combination, healing stack, BPC-157 TB-500 | Cathelicidin LL-37, hCAP-18 C-terminal fragment, CRAMP (murine equivalent) |
| Evidence | Research-stage | Research-stage |
| Dosing range | BPC-157 250mcg + TB-500 2.5mg–BPC-157 750mcg + TB-500 7.5mg varies by component, 2–3x per week | 100mcg–500mcg mcg, Daily or 3–5x weekly |
| Administration | Subcutaneous injection, Intramuscular injection | Subcutaneous injection, Intranasal (for respiratory applications), Topical (wound care) |
| Key side effects | BPC-157: nausea (rare), dizziness, lightheadedness, TB-500: fatigue, headache, injection site reactions, No documented combination-specific adverse effects, Theoretical oncological considerations (angiogenesis stimulation) — relevant in cancer history | Injection site redness and irritation (common — pro-inflammatory at injection site), Transient flu-like symptoms (immune activation), Local induration, High doses may be cytotoxic — dose-response curve is non-linear |
| Cited sources | 2 references | 3 references |
Key differences
- Administration: BPC-157 + TB-500 Stack — Subcutaneous injection, Intramuscular injection; LL-37 — Subcutaneous injection, Intranasal (for respiratory applications), Topical (wound care).
- Dosing units differ: BPC-157 + TB-500 Stack is dosed in varies by component, LL-37 in mcg — they operate at different scales.
- Frequency: BPC-157 + TB-500 Stack is typically 2–3x per week; LL-37 is Daily or 3–5x weekly.
- Research depth: this profile cites 2 sources for BPC-157 + TB-500 Stack vs 3 for LL-37.
How each works
BPC-157 + TB-500 Stack
BPC-157 and TB-500 work through entirely non-overlapping mechanisms and have been combined in numerous community protocols for injury recovery. BPC-157 drives angiogenesis and growth factor receptor expression; TB-500 regulates actin polymerization and cell migration into the injury site. No documented negative interactions exist — the combination is considered synergistic in the healing research community based on the complementary biology of each compound.
LL-37
LL-37 exerts antimicrobial activity by disrupting bacterial membranes via electrostatic interaction with negatively charged lipopolysaccharide — effective against gram-positive and gram-negative bacteria, fungi, and enveloped viruses including SARS-CoV-2 in vitro. Beyond direct antimicrobial action, LL-37 modulates innate immunity through TLR4 signaling, promotes wound healing via EGFR and FPRL1 receptor activation, and has demonstrated anti-biofilm activity against P. aeruginosa and S. aureus. Vitamin D is the primary driver of endogenous LL-37 production.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.